4523 Eisai
- 6183.0
- +246.0+4.14%
Eisai News
Eisai: Treasury stock purchase status report (based on Act Section 24-6 (1))
Eisai: Earnings conference materials for the first quarter of fiscal year 2024.
Eisai: Reference data for the first quarter settlement of the fiscal year 2024 (until March 31, 2025).
Eisai: Consolidated financial statements [IFRS] for the three-month period ended June 30, 2024.
Eisai: Reference materials for the first quarter financial results of the 2024 fiscal year (March 2025).
Eisai: Financial statement for Q1 of March 2025 (consolidated) [IFRS]
Eisai: LEQEMBI's Revenue (Provisional Basis)
Eisai: Regarding the sales revenue (preliminary report) of the anti-amyloid β protofibril antibody 'Leckenbi'.
Eisai: Eisai announces the status of acquiring treasury stock.
Eisai: Announcements of individual stock buyback status.
Eisai: Latest information on the regulatory review of Leconemab for early Alzheimer's disease in the European Union.
Eisai: Regarding the approval review status of Lecanemab in the EU.
Eisai: Report on the Status of Purchases of Treasury Stock by the Company (Based on Article 24-6, Paragraph 1 of the Law)
Eisai: Eisai has announced the transition to developing and commercializing the Farletsuzumab Ecteinascidin-1 Antibody Drug Complex (ADC) on its own.
Eisai: Regarding the antibody drug complex farletuzumab ecteribulin (FZEC), Eisai will transition to global development and commercialization on its own.
Eisai: Eisai announces the status of acquiring treasury stock.
Eisai: Announcements of individual stock buyback status.
Eisai: Position and policy regarding reduction of investment unit in company's stock.
Eisai: Considerations and policies regarding the reduction of investment units.
Eisai: Extraordinary Report
Analysis
Price Target
No Data
